Stryker (NYSE:SYK) Stock Breaks Below Fifty Day Moving Average After Earnings Miss

Stryker Corporation (NYSE:SYK) passed below its fifty day moving average during trading on Friday following a weaker than expected earnings announcement. The stock has a fifty day moving average of $292.83 and traded as low as $282.18. Stryker shares last traded at $291.56, with a volume of 6,437,723 shares.

The medical technology company reported $3.52 earnings per share for the quarter, missing the consensus estimate of $3.55 by ($0.03). The firm had revenue of $6.52 billion during the quarter, compared to analyst estimates of $6.62 billion. Stryker had a net margin of 13.78% and a return on equity of 23.83%. The business’s revenue was up 7.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.19 earnings per share.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is presently 36.48%.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on SYK shares. Stifel Nicolaus cut their price objective on Stryker from $360.00 to $330.00 and set a “buy” rating on the stock in a research report on Wednesday, September 30th. Raymond James Financial reissued an “outperform” rating and issued a $323.00 price target on shares of Stryker in a research report on Friday. Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Citigroup reiterated a “market outperform” rating on shares of Stryker in a research note on Friday. Finally, Barclays reduced their price objective on shares of Stryker from $375.00 to $365.00 and set an “overweight” rating for the company in a research report on Friday. Seventeen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $355.84.

Insider Activity

In other news, Director Ronda Stryker sold 300,000 shares of the stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total transaction of $100,770,000.00. Following the transaction, the director directly owned 2,301,375 shares in the company, valued at $773,031,862.50. This represents a 11.53% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $328.61, for a total transaction of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares in the company, valued at $2,005,178.22. This represents a 6.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 351,267 shares of company stock valued at $118,197,701 in the last 90 days. 4.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Stryker

A number of hedge funds have recently made changes to their positions in SYK. State Street Corp boosted its stake in Stryker by 1.2% in the 2nd quarter. State Street Corp now owns 15,532,565 shares of the medical technology company’s stock worth $4,903,772,000 after purchasing an additional 183,400 shares during the period. Wellington Management Group LLP grew its position in Stryker by 0.6% during the 2nd quarter. Wellington Management Group LLP now owns 8,167,185 shares of the medical technology company’s stock worth $2,571,357,000 after purchasing an additional 45,478 shares in the last quarter. Bank of America Corp DE acquired a new stake in Stryker during the 2nd quarter valued at $1,404,284,000. Royal Bank of Canada raised its stake in Stryker by 6.5% during the 1st quarter. Royal Bank of Canada now owns 3,273,232 shares of the medical technology company’s stock valued at $1,075,552,000 after purchasing an additional 199,863 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Stryker by 21.8% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,689,376 shares of the medical technology company’s stock valued at $846,723,000 after purchasing an additional 481,175 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Down 6.5%

The firm has a market cap of $111.83 billion, a price-to-earnings ratio of 31.05, a PEG ratio of 2.01 and a beta of 0.78. The company has a 50-day moving average price of $292.83 and a 200 day moving average price of $324.51. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.